SURMOUNT-1 Study Finds Individuals with Obesity Lost up to 22.5% of their Body Weight when Taking Tirzepatide – QNT Press Release


American Diabetes Association Symposium to Highlight Once Weekly Drug as Potential Treatment for Obesity

NEW ORLEANS, June 4, 2022 /PRNewswire/ — Today, findings from SURMOUNT-1, the first investigational phase 3 trial evaluating the safety and efficacy of tirzepatide for the treatment of obesity, were announced, representing a new class of medicines being studied for the treatment of obesity. The trial was presented at a symposium at the 82nd Scientific Sessions of the American Diabetes Association® (ADA) in New Orleans, LAand simultaneously published in The New England Journal of Medicine.

Obesity impacts 650 million people worldwide and nearly half of Americans. Obesity is a chronic disease with limited treatment options that increases the risk of other weight-related conditions and negatively impacts overall health. This study aimed to evaluate tirzepatide, a once-weekly GIP (glucose-dependent insulinotropic polypeptide ) and GLP-1 (glucagon-like peptide-1) receptor agonist, for the treatment of obesity.

The study enrolled 2,539 participants who were obese or overweight with at least one weight-related condition, who do not have diabetes. The co-primary endpoints were percent change in body weight from baseline and greater percentage of participants achieving body …

Full story available on Benzinga.com



Source link

Recommended For You

About the Author: News Center